| Sep 12 |
Gilead posts second late-stage win for twice-yearly HIV therapy
|
| Sep 12 |
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
|
| Sep 11 |
Gilead and Genesis partner to create novel therapies using AI
|
| Sep 11 |
Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)
|
| Sep 10 |
Gilead enters into AI drug discovery deal with Genesis Therapeutics
|
| Sep 10 |
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
|
| Sep 8 |
Gilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock?
|
| Sep 6 |
Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)
|
| Sep 6 |
Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey
|
| Sep 6 |
Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
|
